Cosmetic
Alluzience
Ready-to-use BoNT-A neuromodulator in Europe
시술 시간
10-20분
다운타임
0-1일
권장 횟수
3-4개월ごと
이 치료에 대해
Alluzience is a ready-to-use abobotulinumtoxinA product approved in Europe. It is designed to reduce reconstitution steps, preparation time and concentration variability. Approval status must be checked by region.
작용 기전
BoNT-A inhibits acetylcholine release at the neuromuscular junction, temporarily weakening dynamic muscles such as those causing glabellar lines.
적응증
주름·잔주름일반 적응증(상세 설명 참고)
기대 효과
Its clinical positioning builds on abobotulinumtoxinA evidence, with practical advantages from ready-to-use preparation. Onset and duration are explained as BoNT-A class effects.
임상 근거
Galderma (2021)
Alluzience ready-to-use BoNT-A positive European decision. Company / regulatory announcement
해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).
Consensus panel (2024)
International consensus recommendations on aesthetic usage of botulinum toxin type A. Aesthet Surg J Open Forum
해당 연구에서 임상적 개선이 보고되었습니다(자세한 내용은 원문 논문 참조).
위험 및 부작용
Bruising, headache, eyelid ptosis, asymmetry, overcorrection and rare swallowing or breathing symptoms may occur. Unit conversion must not be assumed across brands.